Gentamicins (Gentamicin)

Subscribe to Selected New Research on Gentamicins

4432 relevant articles (507 outcomes, 540 trials/studies) found for this Drug

Description: A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1(subA), obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (GENETIC TRANSLATION).

Also Known As:

Gentamicin; Gentamicin Sulfate; G-Myticin; Garamycin; Gentacycol; Gentamycins; Gentavet; Genticin; G Myticin; GMyticin; Sulfate, Gentamicin; Gentamicin Sulfate (USP); Gentamycin

Relationship Network

Drug Context: Research Results

Experts

1.	Friberg, Orjan: 4 articles (09/2007 - 01/2003)
2.	Källman, Jan: 3 articles (04/2006 - 01/2003)
3.	Wuisman, Paul I J M: 3 articles (06/2005 - 08/2004)
4.	Stallmann, Hein P: 3 articles (06/2005 - 08/2004)
5.	Faber, Christopher: 3 articles (06/2005 - 08/2004)
6.	Bugnon, Denis: 3 articles (10/2004 - 07/2002)
7.	Potel, Gilles: 3 articles (10/2004 - 07/2002)
8.	Caillon, Jocelyne: 3 articles (10/2004 - 07/2002)
9.	Perez, Nicolas: 3 articles (09/2003 - 06/2002)
10.	Rybak, M J: 3 articles (11/2000 - 07/2000)

Related Diseases

1.	Infection 04/11/2006 - "Gentamicin is an aminoglycoside antibiotic that is very effective in treating different gram negative infections, however, one of its main side effects is nephrotoxicity. " 01/01/1977 - "Daily dosages of up to 240 mg (3X80 mg) gentamicin are only effective in infections caused by very susceptible bacteria with a MIC up to 1 microgram/ml." 02/01/1975 - "Gentamicin is in general very effective against these infections. " 05/01/1993 - "The age of infection had a substantial impact on antipseudomonal efficacy of the three study drugs even though high, brief supra-MIC concentrations of gentamicin and persistent supra-MIC concentrations of the beta-lactam drugs were obtained. " 01/01/1991 - "The improved mechanical fixation and the high concentration of gentamicin of the bone cement interface favours the use of low viscosity cement, especially in revision for deep infection." Order ALL the reference details at left...
2.	Endocarditis 02/01/1985 - "The in vitro activity of gentamicin was compared with its therapeutic efficacy in rabbits with Streptococcus faecalis endocarditis. " 11/01/2003 - "This study determined the impact of human pharmacokinetic simulation (HPS) on gentamicin activity in an Enterococcus faecalis endocarditis model. " 07/15/2009 - "Gentamicin in infective endocarditis: how to use it?" 01/01/2009 - "BACKGROUND: Gentamicin is often used to treat infective endocarditis (IE). " 01/01/2009 - "Severity of gentamicin's nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients." Order ALL the reference details at left...
3.	Sepsis (Septicemia) 09/01/2005 - "Because gentamicin improved hemodynamic variables and reduced the fluid requirement in this ovine model, we believe that this modified sepsis model might provide a clinically relevant and useful new approach for future studies focusing on hemodynamic variables and outcome." 06/01/1997 - "The protocol proved simple and effective with a low incidence of gentamicin-associated nephrotoxicity (7%) and no sepsis-related deaths." 06/01/2007 - "The purpose of this study was to determine safe, effective, simplified dosing regimens of gentamicin for treatment of neonatal sepsis in developing countries. " 09/01/2005 - "In this study, we sought to modify this sepsis model by the administration of gentamicin to more closely simulate the symptoms observed in human sepsis in the intensive care unit. " 07/01/2004 - "METHODS: In an open, randomised, controlled trial, infants with suspected severe sepsis admitted to a Kenyan, rural district hospital received a novel, OD gentamicin regimen or routine multi-dose (MD) regimens. " Order ALL the reference details at left...
4.	Vertigo (Positional Vertigo) 11/01/2001 - "CONCLUSIONS: Results of this study on this group of patients indicate that vertigo can be controlled in the long term using microdose gentamicin without a significant reduction in cochlear or vestibular function in most of the patients in our series. " 12/01/2008 - "Although low dose intratympanal gentamicin has empirically been very effective in treating Menière's disease, the mechanisms of elimination or amelioration of vertigo are still insufficiently understood. " 10/01/2003 - "CONCLUSION: Intratympanic gentamicin titration therapy provides excellent vertigo control, with a similarly significant improvement in both personal and occupational functioning." 01/01/2001 - "In more severe cases gentamicin treatment has proved successful; in the present study, vertigo was cured in all but 3 of 35 patients. " 08/01/2008 - "RESULTS: Gentamicin treatment resulted in a significant reduction of the score for vertigo complaints and the score for perceived aural fullness. " Order ALL the reference details at left...
5.	Urinary Tract Infections (Urinary Tract Infection) 11/01/1977 - "21 children with recurrent urinary tract infections (UTI) due to bacteria resistant to the usual antiinfectious drugs were examined to evaluate whether their UTI could be effectively treated with a single daily administration of gentamicin (2.5 mg/kg i.m.) for ten days. " 06/01/1997 - "The results indicate that one bolus dose of gentamicin with early oral therapy is a safe and effective alternative to common parenteral regimens for empirical treatment of febrile urinary tract infection." 03/01/2001 - "OBJECTIVE: To undertake population pharmacokinetic modeling and to determine the safety and efficacy of once daily (OD) gentamicin dosing in children with severe urinary tract infections (UTI). " 01/01/1992 - "Efficacy of prophylactic gentamicin use in postoperative urinary tract infections after endoscopic procedures of the urinary tract." 01/01/1987 - "We evaluated the efficacy of a single dose of gentamicin in patients with normal urinary tracts and in whom urinary tract infections were recurrent. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Clindamycin (Cleocin)
2.	Ampicillin (Omnipen)
3.	Vancomycin
4.	Anti-Bacterial Agents (Antibiotics)
5.	Tobramycin (Nebcin)
6.	Metronidazole (Metric)
7.	Penicillins (Penicillin)
8.	Amikacin (A.M.K)
9.	Ciprofloxacin (Cipro)
10.	Ceftriaxone (Ceftriaxon)

Related Therapies and Procedures

1.	Injections
2.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
3.	Debridement
4.	Peritoneal Dialysis
5.	Vitrectomy

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>